{
    "nct_id": "NCT03591510",
    "official_title": "A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML",
    "inclusion_criteria": "* Documented Diagnosis of previously untreated de novo AML according to WHO 2016 criteria\n* Presence of a FLT3 mutation status as measured/confirmed by a designated lab with results available prior first dose of Midostaurin\n* Patients with Lansky or Karnofsky performance status equal or superior to 60\n* Patient with the following laboratory value : AST and ALT ≤ 3times ULN\n* Serum Total bilirubin ≤ 1.5times ULN\n* Estimated creatinine clearance ≥30ml/min\nHealthy volunteers allowed\nMust have minimum age of 3 Months\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* Any concurrent malignancy, AML with Philadelphia Chromosome, AML-DS, JMML\n* Symptomatic leukemic CNS involvement\n* Isolated extramedullary leukemia, secondary AML and MDS\n* Acute Promyelocytic Leukemia with the PML RARA rearrangement\n* Patient who have received prior treatment with a FLT3 inhibitor. However, up to 1 week of FLT3 inhibitor (except midostaurin) exposure prior to study enrollment is permissible.\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": ""
}